

**SUMMARY OF PRODUCT CHARACTERISTICS
(SmPC) TEMPLATE**

SUMMARY OF PRODUCT CHARACTERISTICS (SMPC)

DR. MEYER'S FOLIC ACID TABLET

1. Name of the medicinal product

Dr. Meyer's Folic Acid Tablets 5mg

2. Qualitative and quantitative composition

Folic Acid 5.00mg

Excipients with known effect

Nipagin (Methyl Paraben) 0.0714mg

Nipasol (Propyl Paraben) 0.0357mg

Corn Starch (Bulk) 56.00mg

Corn Starch (Paste) 1.357mg

Lactose 54.28mg

Gelatin 2.43mg

Purified Talcum 0.93mg

Magnesium Stearate 1.20mg

Purified Water q.s

For the full list of excipients see section 6.1.

3. Pharmaceutical form

Tablet

Yellow circular shaped tablet with 'F' inscribed on one side and 'O' on the other side packed in white HDPE plastic securi container with red press on cap containing 1000 tablets

4. Clinical particulars

4.1 Therapeutic indications

Folic acid is indicated for the treatment of megaloblastic anaemia due to folic acid deficiency. It is also used for prophylaxis in chronic haemolytic states, in renal dialysis, and in drug induced folate deficiency.

Folic acid is used for the prevention of recurrence of neural tube defects.

4.2 Posology and method of administration

Posology

Adults

In folate deficient megaloblastic anaemia:

5mg daily for 4 months

Up to 15mg daily may be necessary for malabsorption states

For prophylaxis in chronic haemolytic states or in renal dialysis:

5mg every 1-7 days depending on diet and underlying disease.

In drug induced folate deficiency:

5mg daily

Prevention of recurrence of neural tube defects

5mg daily starting before conception and continuing throughout the first trimester of pregnancy is recommended.

Paediatric population

Over 1 year : As adult dose

Up to 1 year: 500µg/kg daily

Method of administration

The tablets are for oral use.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Patients with malignant disease, unless megaloblastic anaemia due to folic acid deficiency.

4.4 Special warnings and precautions for use

Folic acid should not be administered for treatment of pernicious anaemia or undiagnosed megaloblastic anaemia without sufficient amounts of cyanocobalamin (vitamin B₁₂) as folic acid alone will not prevent and may precipitate development of subacute combined degeneration of the spinal cord. Therefore a full clinical diagnosis should be made before initiating treatment.

Folate should not be routinely used in patients receiving coronary stents.

Caution should be exercised when administering folic acid to patients who may have folate dependent tumours.

Folic acid is removed by haemodialysis.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Absorption of folic acid may be reduced by sulfasalazine.

Concurrent administration with cholestyramine may interfere with folic acid absorption. Patients on prolonged cholestyramine therapy should take folic acid 1 hour before or 4 to 6 hours after receiving cholestyramine.

Antibiotics may interfere with the microbiological assay for serum and erythrocyte folic acid concentrations and may cause falsely low results.

Trimethoprim or sulfonamides, alone or in combination as co-trimoxazole, may reduce the effect of folic acid and this may be serious in patients with megaloblastic anaemia.

Serum levels of anticonvulsant drugs (phenytoin, phenobarbital, primidone) may be reduced by administration of folate and therefore patients should be carefully monitored by the physician and the anticonvulsant drug dose adjusted as necessary.

Fluorouracil toxicity may occur in patients taking folic acid and this combination should be avoided.

Edible clay or antacids containing aluminium or magnesium may reduce folic acid absorption. Patients should be advised to take antacids at least two hours after administration of folic acid.

Folic acid may reduce intestinal absorption of zinc (of particular importance in pregnancy).

4.6 Fertility, pregnancy and lactation

Pregnancy

Folic acid deficiency during pregnancy may lead to the appearance of foetal malformations. Imbalance in folate requiring trophoblast cells may also lead to detachment of the placenta.

Very high doses of folic acid have been shown to cause foetal abnormalities in rats; however, harmful effects in the human foetus, mother or the pregnancy have not been reported following ingestion of folic acid.

Breastfeeding

Folic acid is excreted in breast milk.

No adverse effects have been observed in breast-fed infants whose mothers were receiving folic acid.

4.7 Effects on ability to drive and use machines

None known

4.8 Undesirable effects

Folic acid is generally well tolerated although the following side effects have been reported:

Blood and lymphatic system disorders:

Folic acid may worsen the symptoms of co-existing vitamin B₁₂ deficiency and should never be used to treat anaemia without a full investigation of the cause.

Immune system disorders:

Rare: Allergic reactions, comprising erythema, rash, pruritus, urticarial, dyspnoea, and anaphylactic reactions (including shock).

Gastrointestinal disorder:

Abdominal distension, flatulence, anorexia and nausea.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

No cases of acute overdosage appear to have been reported, but even extremely high doses are unlikely to cause harm to patients. No special procedures or antidote are likely to be needed.

5. Pharmacological properties

5.1 Pharmacodynamic properties

The mucosa of the duodenum and upper part of the jejunum are rich in dihydrofolate reductase, where folates and folic acid are absorbed. Once absorbed, folic acid is rapidly reduced and then methylated to form tetrahydrofolic acid derivatives which are rapidly transported to the tissues.

5.2 Pharmacokinetic properties

Folic acid is readily absorbed following oral dosage, and is extensively bound to plasma proteins.

5.3 Preclinical safety data

Toxicity studies in animals (rats and rabbits) have shown that massive doses (100mg/kg upwards) produce precipitation of folate crystals in renal tubules, particularly proximal tubules and ascending limb of the loop of Henle. Tubular necrosis is followed by recovery.

6. Pharmaceutical particulars

6.1 List of excipients

Nipagin (Methyl Paraben)	0.0714mg
Nipasol (Propyl Paraben)	0.0357mg
Corn Starch (Bulk)	56.00mg
Corn Starch (Paste)	1.357mg
Lactose	54.28mg
Gelatin	2.43mg
Purified Talcum	0.93mg
Magnesium Stearate	1.20mg
Purified Water	q.s

6.2 Incompatibilities

None known

6.3 Shelf life

3 years for tablets in polypropylene or polyethylene containers or glass bottles.

3 years for tablets in strip packs of opaque white or clear PVC film and 20µm aluminium foil.

6.4 Special precautions for storage

Store in the original package in order to protect from light

Do not store above 30°C

6.5 Nature and contents of container

White HDPE plastic securi container with red press on cap containing 1000 tablets

6.6 Special precautions for disposal and other handling

No special requirements.

7. Applicant / Manufacture:

Vitabiotics Nigeria Limited

35, Mobolaji Johnson Avenue,

Oregun Industrial Estate,

Ikeja, Lagos,

Nigeria.